Opendata, web and dolomites

InDx SIGNED

InDx - an innovative implant that restores natural motion to patients with thumb base joint arthritis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 InDx project word cloud

Explore the words cloud of the InDx project. It provides you a very rough idea of what is the project "InDx" about.

24       start    running    movement    launch    spin    substantial    million    approximately    joint    market    opening    clinical    expertise    sme    europeans    natural    ireland    led    cumulative    stages    door    first    indx    dressed    company    fda    dexterity    suffers    burden    base    fundamental    germany    stage    dynamic    irish    jar    international    organization    marking    medvie    510k    validate    51m    extensive    lags    implant    25    ce    human    investigations    debilitating    university    endolab    disruptive    surgical    innovation    medical    implants    trl    approval    orthopaedics    thumb    joints    arthritis    functional    impossible    employment    causes    prone    months    accommodate    healthcare    galway    biomechanics    restore    commercialization    uk    treatment    namsa    date    ftes    socioeconomic    estimates    world    revenues    prepare    designed    usa    commercialisation    final    anatomy    small    population    station    humanitarian    loci    national   

Project "InDx" data sheet

The following table provides information about the project.

Coordinator
LOCI ORTHOPAEDICS LIMITED 

Organization address
address: UNIT 209 NUIG BUSINESS INNOVATION CENTRE UPPER NEWCASTLE
city: GALWAY
postcode: H91 V207
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙633˙125 €
 EC max contribution 2˙543˙187 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LOCI ORTHOPAEDICS LIMITED IE (GALWAY) coordinator 1˙746˙500.00
2    NORTH AMERICAN SCIENCE ASSOCIATES LIMITED UK (SELBY) participant 319˙812.00
3    Medvie Limited IE (MALAHIDE) participant 280˙000.00
4    ENDOLAB MECHANICAL ENGINEERING GMBH DE (RIEDERING) participant 196˙875.00

Map

 Project objective

The thumb base joint is fundamental for human dexterity and functional activity but is prone to debilitating arthritis. Approximately 5% of the world population suffers from this condition with over 25 million Europeans affected. Simple tasks become impossible such as getting dressed, opening a jar, using a key to open a door. This is certainly a relevant socioeconomic and humanitarian concern, which causes a substantial cost burden on healthcare systems, yet the effective treatment for end-stage thumb base arthritis lags far behind other joints, given challenges of the small, complex anatomy. The InDx project aims to enable the commercialization of the InDx implant, the world’s first implant designed to accommodate the complex biomechanics of the thumb base joint and restore the natural movement of the thumb. The consortium is led by Loci Orthopaedics, a technology-driven SME spin-out company from the National University of Ireland, Galway. The partners include EndoLab in Germany, that has developed a novel dynamic test station for implants, NAMSA in the UK, a leading medical research organization with extensive experience in running international clinical investigations, and Medvie, an Irish based SME with extensive project management, dissemination and commercialization expertise. Together, the consortium have brought the implant to TRL 6 level. As part of the InDx project, the consortium will undertake the final stages of product development and will validate clinical results in a clinical study that will prepare the CE marking and market access. Market launch is planned within 24 months from the project start date, following FDA 510K approval in the USA and CE marking in Europe. The consortium estimates cumulative revenues of €51M within 5 years from the start of commercialisation and an employment growth of 25 FTEs for the consortium partners. The InDx has the potential to be a disruptive innovation in the surgical management of thumb base joint arthritis.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INDX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INDX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

PAV-DT (2019)

A disruptive technology that enables low cost real-time monitoring of road pavement condition by any ordinary vehicle circulating on the road, and automatically designs plans for predictive maintenance.

Read More  

Bio-LP-1 (2020)

A novel rapid environmental test for the human pathogen Legionella

Read More  

De-RISC (2019)

De-RISC: Dependable Real-time Infrastructure for Safety-critical Computer

Read More